News

Coaches, Parents Offered Brain Injury Information at "Cutting Edge Concussion Summit" Conference

Children’s of Alabama was host to the inaugural “Cutting Edge Concussion Summit- Maintaining the Competitive Edge” on Friday, June 13, at 8 a.m. in its Bradley Lecture Center. The Summit attracted approximately 200 attendees.

The day-long conference was open to the public and hosted by UAB Sports Medicine at Children’s in conjunction with the Wise Up! Initiative. The conference featured presentations geared to coaches, athletic trainers and parents. Sessions included Critical Changes in Concussion Culture, Epidemiology of Sports and Recreation-Related TBI, and a panel discussion on Prolonged Recovery from Concussion among others.

“The evolution of concussion legislation and best practice is ongoing,” said Drew Ferguson, director of UAB Sports Medicine at Children’s of Alabama. “It’s imperative to understand how young athletes are affected by concussion symptoms in both the short term and the long term. The more parents, athletic trainers and coaches know about concussions, the safer our young athletes will be.”

Speakers included former college and NFL players including John Parker Wilson, Chris Redman and Tyler Watts as well as representatives from the CDC, renowned pediatric neurosurgeon Dr. Jim Johnston and Alabama High School Athletic Association Director, Steve Savarese. Topics that were addressed included Return-to-Play and Return-to –Think legislature as well as helmet standards, diagnosis and management of concussions and establishing a multi-disciplinary concussion program. Joel Stitzel and Alex Powers from Wake Forest University presented their groundbreaking research on impact biomechanics of youth football.

Children’s of Alabama has provided specialized medical care for ill and injured children across the state and throughout the southeastern U.S. since 1911. For the past four years, Children’s has been ranked among the best children’s hospital programs in the nation by US News & World Report. Last year, patients made more than 670,000 outpatient and nearly 14,000 inpatient visits to Children’s from every county in Alabama and from 41 other states and four foreign countries. With more than 2 million square feet, it is the third largest pediatric medical facility in the U.S. Children’s offers inpatient and outpatient services across its Russell Campus on Birmingham’s historic Southside with additional outpatient services provided at Children’s South and Children’s on 3rd. Primary care is provided at more than a dozen medical offices in communities across central Alabama. Children’s of Alabama is the only medical center in Alabama dedicated solely to the care and treatment of children. It is a private, not-for-profit medical center that serves as the primary site of the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, research and residency programs. Children’s recently moved much of its inpatient services into a new building named The Benjamin Russell Hospital for Children. More information is available at www.childrensal.org.

Original source: https://www.childrensal.org/body.cfm?id=1730&action=detail&ref=313

 

 

 

 

 

 

 

 

 

 

UAB-developed viral therapy shows promise against brain tumors

Researchers at the University of Alabama atMarketinClinic Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer.

The virus, G207, is a modified herpes simplex virus that in two previous UAB studies has been shown to be safe when used as a sole therapy. The new findings, published April 8, 2014 in Molecular Therapy, indicate the virus is also safe when used in combination with low doses of radiation therapy.

The study examined nine patients with malignant glioma, and all nine tolerated the therapy well. None developed encephalitis, the brain inflammation often associated with herpes simplex; the gene responsible for causing encephalitis has been removed from G207. Some patients also showed evidence of tumor reduction, and survival rates were increased for others.

“This was a phase one study designed foremost to see whether the therapy was safe,” said James M. Markert, M.D., Ph.D., professor and chair of the Department of Neurosurgery at UAB and the study’s first author. “While this study, with a limited number of patients and no controls, prevents any conclusions about the efficacy of this treatment, the decrease in tumor size seen on MRI’s in some patients, as well as an increase in survival in some patients without other proven treatment options, is highly encouraging.”

G207 was administered directly to glioma cells in the brain, followed the next day by a low-dose radiation treatment.

The virus works by infecting tumor cells and replicating until it overwhelms the cell’s machinery and causes the cell to rupture and die, releasing new viral particles. The virus has been genetically modified so that it can reproduce only in tumor cells, which lack the stronger antiviral defense mechanisms of healthy brain cells. After destroying a tumor cell, the virus moves on, looking for new tumor cells to infect.

While the study was designed for each patient to receive one dose of G207, two of the nine patients received a second dose as part of a compassionate-use protocol.

“While we cannot draw any firm conclusions from just two study subjects, we are encouraged to note that both of the compassionate-use patients tolerated the second dose extremely well, indicating that the drug may be suitable for multiple use,” said Markert.

UAB is gearing up for another study with a new modified version of herpes simplex virus called M032. Preliminary studies have indicated M032 could be an even more effective therapy. It includes a genetically engineered protein called IL12, which the researchers believe will induce a stronger immune response and will contribute to increased anti-angiogenesis, the process of shutting off the blood supply to tumor cells, denying oxygen and essential nutrients.



Dr. John P. Deveikis Joins Department of Neurosurgery

Dr. John P. Deveikis, M.D., joined the UAB Department of Neurosurgery as Professor on March 1, 2014. Dr. Deveikis is a Neuroradiologist who characterizes and diagnoses neurological disorders through the use of medical imaging modalities. He comes to UAB from St. Petersburg, FL as an Interventional Neuroradiologist at All-Children’s Hospital and Bayfront Medical Center.

Dr. Deveikis’ previous academic appointments include Professor of Radiology and Neurosurgery at the University of Rochester, Professor of Radiology and Neurosurgery at the Medical University of South Carolina, Clinical Associate Professor of Neurosurgery at the University of Michigan Medical Center, Clinical Associate Professor of Radiology at the University of Michigan Medical Center, Assistant Professor of Radiology at the University of Michigan Medical Center, and Assistant Professor of Radiology at Georgetown University.            

He has served as a professional consultant in Interventional Neuroradiology at Walter Reed Army Medical Center, the National Naval Medical Center, and Georgetown University Hospital.

Dr. Deveikis received his Medical Degree from the University of Massachusetts Medical                School. He completed his fellowship training in Neuroradiology, at Georgetown University Medical Center and the University of Western Ontario.

Dr. Deveikis has presented for the American Society of Neuroradiology and the American Association of Neurological Surgeons, as well as many other professional and scientific organizations and conferences. He has over 49 published articles and is the co-author of Handbook of Cerebrovascular Disease and Neurointerventional Technique, 1st and 2nd Editions.

His major research interests are focusing on ways to make neurinterventional techniques more effective and safer, application of perfusion imaging techniques to neurovascular conditions to tailor interventions based on perfusion data, and avoidance of complications based on modifications of technique and patient selection.

Appointments can be made with Dr. Deveikis, by referral, by calling 205-934-7170.

30th Annual J. Garber Galbraith Scientific Session & Lecture

The 30th Annual J. Garber Galbraith Scientific Session & Lecture will be held at the Bradley Lecture Center at Children's Harbor on Friday, November 8, 2013. The Scientific Session hours are 10:00 a.m. until 3:00 p.m.

The main lecture, "Low Grade Gliomas: from Bench to Bedside," will be presented by Mitchel S. Berger, MD.

For further information, click here.

UAB Neurosurgeons Recognized by Congress for Spinal Injury Guidelines

On September 27, 2013, in recognition of Spinal Cord Injury Awareness Month, the Congress of the United States honored contributors of the updated Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries. Authors include UAB neurosurgeons Mark N. Hadley, MD, Beverly C. Walters, MD, Mark R. Harrigan, MD, and Curtis J. Rozzelle, MD. Doctors Hadley and Walters co-chaired the nine-member committee. To learn more about this important contribution to the field of neurosurgery, read the Congressional letter of recognition, signed by congress members representing the home states of the authors.

Taped Remarks from Congressman Jim Langevin at the Annual North American Spine Society (NASS) Meeting


 

Jim Langevin at the North American Spine Society Meeting from UAB School of Medicine on Vimeo.

Congressman Jim Langevin of Rhode Island, who is quadriplegic, addressed the North American Spine Society at their annual meeting, held October 9-12, 2013. His remarks included the story of how he became paralyzed, and he expressed his gratitude to the health care providers who assisted in his recovery. He also commended the authors of the updated Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries, published in the March 2013 issue of Neurosurgery.